ASX:API

Australian Pharmaceutical Industries (API) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
453,647 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
2.29%
Price Target
N/A
API stock logo

About Australian Pharmaceutical Industries Stock (ASX:API)

Australian Pharmaceutical Industries Limited engages in the wholesale distribution of pharmaceutical, medical, health, beauty, and lifestyle products to pharmacies primarily in Australia. It also retails health and beauty products to consumers through a network of Priceline and Priceline Pharmacy franchise stores, and company owned Priceline stores in Australia; sells beauty products through Clear Skincare network of clinics in Australia and New Zealand; and manufactures and distributes pharmaceutical and toiletry goods to New Zealand, Australian, and Asian markets, as well as provides cosmetic products and non-invasive aesthetic beauty services. The company was founded in 1910 and is based in Camberwell, Australia.

API Stock News Headlines

World’s biggest multibillionaire investor is buying THIS by the ton [picture]
Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.
World’s biggest multibillionaire investor is buying THIS by the ton [picture]
Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.
See More Headlines
Receive API Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Australian Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/17/2019
Today
4/26/2024

Industry, Sector and Symbol

Industry
Medical Equipment Wholesale
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
2,020
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.00 billion
Book Value
A$0.89 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Richard C. Vincent C.P.A.
    B.Bus, (Accountancy), CPA, MD, CEO & Exec. Director
  • Mr. Peter Mendo
    Chief Financial Officer
  • Mr. Dean Matthews
    Chief Information Officer
  • Ms. Anne Mustow B.Com.
    L.L.B., Gen. Counsel & Company Sec.
  • Mr. Stephen Arthurson
    Gen. Mang. of People
  • Mr. D. Glance
    NSW State Mang.

API Stock Analysis - Frequently Asked Questions

How were Australian Pharmaceutical Industries' earnings last quarter?

Australian Pharmaceutical Industries Limited (ASX:API) posted its quarterly earnings results on Wednesday, April, 17th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.05 by $0.00.

Is Australian Pharmaceutical Industries a good dividend stock?

Australian Pharmaceutical Industries (ASX:API) pays an annual dividend of A$0.04 per share and currently has a dividend yield of 2.29%. The dividend payout ratio is 1,333.33%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for API.

What other stocks do shareholders of Australian Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Australian Pharmaceutical Industries investors own include Capricorn Metals (CMM), Austal (ASB), Mod Resources (MOD), Harvey Norman (HVN), Evolution Mining (EVN) and Downer EDI (DOW).

This page (ASX:API) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners